Actuate Therapeutics Prices $11 Million Public Offering of Common Stock and Warrants
Actuate Therapeutics (ACTU) has finalized the pricing for an underwritten public offering consisting of 30.98 million shares of common stock alongside warrants to purchase up to 15.49 million additional shares. The total offering is valued at approximately $11 million. The capital raise provides the biotechnology company with additional liquidity to support its ongoing operations and clinical development programs. This type of financing is a standard mechanism for mid-stage biotech firms to fund research and regulatory milestones.
Topics: Public Offering Stock Issuance Warrants